Seagen’s $43B Deal To Double Pfizer’s Early-Stage Oncology Pipeline, Seagen Says Is Right Step
Pfizer Inc (NYSE:PFE) has agreed to acquire Seagen Inc (NASDAQ:SGEN) for $229 in cash per Seagen share for a total enterprise value…
Why Prevention Bio Stock Is Rocketing Past 52-Week Highs Today
Provention Bio Inc (NASDAQ: PRVB) shares are rocketing higher Monday after Sanofi (NASDAQ: SNY) announced plans to acquire the biopharmaceutical company.</
Pfizer Is Sending Seagen Stock Soaring Monday: What’s Going On?
Seagen Inc (NASDAQ: SGEN) shares are trading higher Monday after Pfizer Inc (NYSE: PFE) announced plans to acquire the global biotech company.
Centers For Medicare & Medicaid Services Approves Transitional Pass-through Reimbursement Status For Harrow’s Iheezo (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% For Ocular Surface Anesthesia
Beginning April 1, 2023, and for the three years thereafter, IHEEZO will be eligible for separate reimbursement outside of the surgical bundled payment in both the Ambulatory Surgery Center (ASC) and Hospital
Eagle Pharmaceuticals Sees FY23 Adjusted EPS Of $4.20-$4.53 Vs. Consensus of $4.49
Expects 2023 Adjusted EBITDA of $74.0-$80.0 million
EXCLUSIVE: BioRestorative Seeks Expanded FDA Approval For BRTX-100 Clinical Application, Engages Advisory Firm
BioRestorative Therapies Inc (NASDAQ: BRTX) has entered into an agreement with Bruder Consulting & Venture Group, a full-service strategic advisory, to assist the company in seeking FDA approval for the expanded clinical application of BRTX-100.
Sanofi Has Agreed To Acquire Provention Bio For $25.00/Share In Cash, Representing An Equity Value Of Approximately $2.9B
https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-13-06-00-00-2625367
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per patient monthly when it launched in 2021.
FDA Addresses ‘Misinformation’ Concerning Delayed Approval Of Lucira Health’s COVID-19 & Flu Home Test
The FDA provided additional information about the agency’s interactions and decisions regarding the emergency use authorization (EUA) of Lucira Health Inc’s (OTC: LHDXQ)…